Quantumup
Oct 15, 3:06 PM
Rodman & Renshaw (a/o 10/12)🏁
$COAG Buy; PT
$56
$INCY $NVO
Rodman & Renshaw said -- We are initiating coverage of Hemab Therapeutics with a BUY rating and
$56 price target based on sutacimig's path to becoming the first approved prophylactic therapy in Glanzmann thrombasthenia, backed by a second engine in Von Willebrand disease.
Hemab has spent nearly a decade on coagulation disorders that larger hematology franchises left behind, where decades-old plasma products and short-acting bypassing agents have never given way to a subcutaneous, prophylactic option.
